Skip to main content

ABBOTT RECEIVES CE MARK FOR AVEIR™ DR, THE WORLD'S FIRST DUAL CHAMBER LEADLESS PACEMAKER SYSTEM

Written by: Editor
Published on: 7 Jun 2024

Abbott

  • Abbott's first-of-its-kind i2i™ technology enables synchronized communication between two leadless pacemakers
  • The AVEIR™ DR leadless pacemaker system is roughly one-tenth the size of a traditional pacemaker and smaller than a AAA battery
  • AVEIR DR leadless pacemakers are designed to address the needs of people in Europe living with abnormal heart rhythms and expand treatment options for Europeans

ABBOTT PARK, Ill., June 6, 2024 ­­­­— Abbott today announced it has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. Approximately 49 million people are living with cardiovascular disease in the European Union, and it is estimated that 14.4 million people 65 and older will have atrial fibrillation by 2060.1 2  AVEIR DR is a breakthrough innovation that enables the world's first beat-to-beat, wireless communication between two leadless pacemakers, designed to address the needs of people living with abnormal heart rhythms and expand treatment options in Europe.

The AVEIR DR leadless pacemaker system utilizes a new method of delivering dual chamber therapy as it is comprised of two unique devices – one that paces the right ventricle (AVEIR VR) and one that paces the right atrium (AVEIR AR). Each device is roughly one-tenth the size of a traditional pacemaker and smaller than a AAA battery.

A traditional pacemaker is a small battery-powered device implanted underneath the skin in the chest through a surgical procedure. The device delivers electrical therapy to the heart via thin insulated wires better known as cardiac leads, and often leaves a chest scar and device bulge that is visible. Unlike traditional pacemakers, leadless devices are implanted directly into the heart through a minimally invasive procedure, eliminating cardiac leads. As a result, leadless pacemakers reduce people's exposure to potential lead and infection-related complications and offer a less restrictive and shorter recovery period post-implantation.

"Receiving CE Mark for AVEIR DR is a historic moment in European cardiac care. This technology redefines how we approach the treatment of heart rhythm abnormalities," said Professor Reinoud Knops, M.D. PhD, from the department of cardiac electrophysiology at the Amsterdam University Medical Center. "As the world's first dual chamber leadless pacemaker, AVEIR DR is a game changer, expanding our capacity to address complex heart conditions, and significantly reducing complication risk3 and enhance patient comfort."

Through Abbott's proprietary i2i™ (implant-to-implant) communication technology, AVEIR DR provides synchronized pacing between two leadless pacemakers on every heartbeat based on a person's clinical needs. The i2i technology utilizes high-frequency pulses to relay messages via the naturally conductive characteristics of the body's blood between the paired, co-implanted devices. Conductive communication uses far less battery current than inductive, radio-frequency, or Bluetooth® communication, which are alternatives often used in implantable medical devices or traditional pacemakers.

"Since its inception, pacemaker technology has remained fundamentally unchanged as seamless synchronization of two leadless pacemakers has been a significant challenge," said Leonard Ganz, M.D., divisional vice president of medical affairs and chief medical officer at Abbott's cardiac rhythm management business. "AVEIR DR addresses a critical need for people living with slow heart rhythms and enhances people's quality of life with its revolutionary leadless design."

The AVEIR DR i2i Global Clinical Investigation study showed that AVEIR DR met its three prespecified primary endpoints for safety and efficacy. Results through three-months post-implant showed a 98.3% system implant success rate and more than 97% of people had a successful atrio-ventricular synchrony, so that the upper and lower chambers were beating normally, despite different postures and gaits.4

The AVEIR DR leadless pacemaker system received U.S. FDA approval in June 2023.

For important safety information on the AVEIR DR leadless pacemaker system, visit: https://bit.ly/3EiSBp6

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedInFacebookInstagramX and YouTube.

Bluetooth is a registered trademark of Bluetooth SIG, Inc.
 


Fact Sheets for Press. European Society of Cardiology. (n.d.-a). https://www.escardio.org/The-ESC/Press-Office/Factsheets

Atrial fibrillation set to affect more than 14 million over-65s in the EU by 2060. European Society of Cardiology. (n.d.). https://www.escardio.org/The-ESC/Press-Office/Press-releases/Atrial-fibrillation-set-to-affect-more-than-14-million-over-65s-in-the-EU-by-2060

3 Knops RE, Reddy VY, Ip JE, et al. A Dual-Chamber leadless pacemaker. New England Journal of Medicine (Print). 2023;388(25):2360-2370. doi:10.1056/nejmoa2300080

4 Daniel J. Cantillon, Srinivas R. Dukkipati, et al. Comparative study of acute and mid-term complications with leadless and transvenous cardiac pacemakers. Heart Rhythm, Volume 15, Issue 7, 2018, Pages 1023-1030, ISSN 1547-5271, https://doi.org/10.1016/j.hrthm.2018.04.022 Knops RE, Reddy VY, Ip JE, et al. A

 

For further information: Abbott Media: Alicia Swanson (669) 210-7204; Abbott Financial: Mike Comilla (224) 668-1872